Evidence map›Paper›PMID 40849803›Full record

ArticleInternational journal of oncology2025

Harnessing TP73‑targeted nintedanib: A novel strategy to halt triple‑negative breast cancer via p53‑PPARα/PI3K‑Akt pathway suppression.

Xiaomeng Zou, Shiyu Li, Sisi Huang, Ruilan Niu, Gang Liu, Zhili Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaomeng ZouDepartment of Ultrasound, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China.
Shiyu LiDepartment of Ultrasound, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China.
Sisi HuangDepartment of Ultrasound, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China.
Ruilan NiuDepartment of Ultrasound, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China.
Gang LiuDepartment of Radiology, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China.
Zhili WangDepartment of Ultrasound, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple‑negative breast cancer (TNBC) is an aggressive malignancy with limited treatment options, leading to poor clinical outcomes and the need for novel therapeutic approaches. Nintedanib, a United States Food and Drug Administration‑approved multi‑kinase inhibitor with anti‑fibrotic and anti‑angiogenic properties, has shown promise in cancer treatment. However, its precise molecular effects on TNBC have not yet been fully elucidated. Therefore, the present study aimed to investigate the therapeutic potential of nintedanib in TNBC using

Indexed as

IndolesTriple Negative Breast NeoplasmsTumor Protein p73AnimalsApoptosisCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMiceMice, Inbred BALB CPhosphatidylinositol 3-KinasesPPAR alphaProto-Oncogene Proteins c-aktIndolesnintedanibPhosphatidylinositol 3-KinasesPPAR alphaProto-Oncogene Proteins c-aktTP53 protein, humanTP73 protein, humanTumor Protein p73Tumor Suppressor Protein p53apoptosisepithelial‑mesenchymal transitionnintedanibtargeted therapytriple‑negative breast cancertumor protein p73

Identifiers

PMID40849803
PMCPMC12425344

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.